Amylyx Publishes CENTAUR Survival Data Demonstrating Statistically Significant Survival Benefit of AMX0035 for People with ALS

lesturner Foundation Blog, Home Page, Research & The Les Turner ALS Center

We are excited to share some promising data regarding the CENTAUR trial evaluating AMX0035 in people with ALS on overall survival analysis, published today (October 16, 2020)  in the neuromuscular disease journal Muscle & Nerve. The survival analysis followed each …

Data from Amylyx’s CENTAUR trial shows promise in slowing ALS progression

lesturner Foundation Blog, Home Page, Research & The Les Turner ALS Center

We are very pleased to share promising data published this week in the New England Journal of Medicine from the recent CENTAUR trial, conducted by Amylyx Pharmaceuticals, showing that AMX0035, the combination drug of sodium phenylbutyrate–taurursodiol, can slow functional decline …

August 2020 Foundation eNews

lesturner Advocacy, Foundation eNews, Home Page, Research & The Les Turner ALS Center, Support Services

New and Improved Clinical Trials Webpage While it may feel like much in life is on pause at the moment, there is exciting news in the ALS clinical trials and studies space, including information on the upcoming HEALEY ALS Platform …

Introducing the First-Ever ALS Platform Trial

lesturner Home Page, Research & The Les Turner ALS Center

The Sean M. Healey & AMG Center at Massachusetts General Hospital is launching the first-ever ALS platform trial aimed at advancing the development of ALS treatments. Our Lois Insolia ALS Clinic at the Les Turner ALS Center at Northwestern Medicine …